Methods to produce a human plasma-derived IgG preparation enriched in brain disease-related natural iggs
The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-Aβ, anti-RAGE, and anti-α-synuclein antibodies), are also provided.
1. An aqueous plasma-derived immunoglobulin G composition enriched in anti-amyloid β immunoglobulins, comprising:
a content of at least 1% anti-amyloid β fibril immunoglobulin G;
a content of at least 0.4% anti-amyloid β oligomer immunoglobulin G;
a content of at least 0.2% anti-amyloid β monomer immunoglobulin G and a pharmaceutically acceptable stabilizing agent.
2. The plasma-derived immunoglobulin G (IgG) composition enriched in anti-amyloid β immunoglobulins of claim 1 , further comprising:
a titer of anti-RAGE immunoglobulin G that is at least 5-fold greater than the titer of anti-RAGE immunoglobulin G in an average pool of plasma from more than 1000 random plasma donors.
3. The plasma-derived immunoglobulin G (IgG) composition enriched in anti-amyloid β immunoglobulins of claim 1 , further comprising:
a titer of anti-α-synuclein immunoglobulin G that is at least 5-fold greater than the titer of anti-α-synuclein immunoglobulin G in an average pool of plasma from more than 1000 random plasma donors.
4. The plasma-derived immunoglobulin G (IgG) composition enriched in anti-amyloid β immunoglobulins of claim 1 , comprising:
a content of at least 2.5% anti-amyloid β fibril immunoglobulin G;
a content of at least 1% anti-amyloid β oligomer immunoglobulin G; and
a content of at least 0.5% anti-amyloid β monomer immunoglobulin G.
5. The plasma-derived immunoglobulin G (IgG) composition enriched in anti-amyloid β immunoglobulins of claim 4 , further comprising:
a titer of anti-RAGE immunoglobulin G that is at least 5-fold greater than the titer of anti-RAGE immunoglobulin G in an average pool of plasma from more than 1000 random plasma donors.
6. The plasma-derived immunoglobulin G (IgG) composition enriched in anti-amyloid β immunoglobulins of claim 4 , further comprising:
a titer of anti-α-synuclein immunoglobulin G that is at least 5-fold greater than the titer of anti-α-synuclein immunoglobulin G in an average pool of plasma from more than 1000 random plasma donors.
7. The plasma-derived immunoglobulin G (IgG) composition enriched in anti-amyloid β immunoglobulins of claim 1 , comprising:
a content of at least 5% anti-amyloid β fibril immunoglobulin G;
a content of at least 2% anti-amyloid β oligomer immunoglobulin G; and
a content of at least 1% anti-amyloid β monomer immunoglobulin G.
8. The plasma-derived immunoglobulin G (IgG) composition enriched in anti-amyloid β immunoglobulins of claim 7 , further comprising:
a titer of anti-RAGE immunoglobulin G that is at least 5-fold greater than the titer of anti-RAGE immunoglobulin G in an average pool of plasma from more than 1000 random plasma donors.
9. The plasma-derived immunoglobulin G (IgG) composition enriched in anti-amyloid β immunoglobulins of claim 7 , further comprising:
a titer of anti-α-synuclein immunoglobulin G that is at least 5-fold greater than the titer of anti-α-synuclein immunoglobulin G in an average pool of plasma from more than 1000 random plasma donors.
10. The plasma-derived immunoglobulin G (IgG) composition enriched in anti-amyloid β immunoglobulins of claim 1 , wherein the pharmaceutically acceptable stabilizing agent is glycine.
11. A method for treating Alzheimer's disease comprising: administering a therapeutically effective amount of a plasma-derived immunoglobulin G composition enriched in anti-amyloid β immunoglobulins according to any one of claims 1 - 9 and 10 .